EXTON, PA -- (MARKET WIRE) -- April 16, 2007 -- Rheologics Technologies, Inc. (“Rheologics” or the “Company”) (PINKSHEETS: RTGI), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announces today its commitment to the development of measures to monitor and treat diabetes complications.
